The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery
Open accessAbstract
Drug discovery is an extensive and rigorous process that requires up to 2 billion dollars of investments and more than ten years of research and development to bring a molecule “from bench to a bedside”. While virtual screening can significantly enhance drug discovery workflow, it ultimately lags the current rate of expansion of chemical databases that already incorporate billions of purchasable compounds. This surge of available small molecules presents great opportunities for drug discovery but also demands for faster virtual screening methods and protocols. In order to address this challenge, we herein introduce Deep Docking ( D 2 ) - a novel deep learning-based approach which is suited for docking billions of molecular structures. The developed D 2 -platform utilizes quantitative structure-activity relationship (QSAR) based deep models trained on docking scores of subsets of a large chemical library (Big Base) to approximate the docking outcome for yet unprocessed molecular entries and to remove unfavorable structures in an iterative manner. We applied D 2 to virtually screen 1.36 billion molecules form the ZINC15 library against 12 prominent target proteins, and demonstrated up to 100-fold chemical data reduction and 6,000-fold enrichment for top hits, without notable loss of well-docked entities. The developed D 2 protocol can readily be used in conjunction with any docking program and was made publicly available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199
ZINC − A Free Database of Commercially Available Compounds for Virtual Screening
Irwin, J. J., & Shoichet, B. K. (2005) · Journal of Chemical Information and Modeling · doi:10.1021/ci049714+ · Cited by 4,058
Innovation in the pharmaceutical industry: New estimates of R&D costs
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016) · Journal of Health Economics · doi:10.1016/j.jhealeco.2016.01.012 · Cited by 3,359
Molecular basis of agonism and antagonism in the oestrogen receptor
Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355
ZINC 15 – Ligand Discovery for Everyone
Sterling, T., & Irwin, J. J. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00559 · Cited by 3,224
Principles of early drug discovery
Hughes, J., Rees, S., Kalindjian, S., & Philpott, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01127.x · Cited by 2,859
A comprehensive map of molecular drug targets
Santos, R., Ursu, O., Gaulton, A., Bento, A. P., Donadi, R. S., Bologa, C. G., Karlsson, A., Al-Lazikani, B., Hersey, A., Oprea, T. I., et al. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.230 · Cited by 2,427
Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking.
Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300687e · Cited by 2,412
The rise of deep learning in drug discovery
Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.039 · Cited by 1,770
Hawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A., & Stahl, M. T. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100031x · Cited by 1,607
Cited by
Ton, A., Gentile, F., Hsing, M., Ban, F., & Cherkasov, A. (2020) · Molecular Informatics · doi:10.1002/minf.202000028 · Cited by 517
Self-citationVidal-Limon, A., Aguilar-Toalá, J. E., & Liceaga, A. M. (2022) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c06110 · Cited by 514
Efficient Exploration of Chemical Space with Docking and Deep Learning
Yang, Y., Yao, K., Repasky, M. P., Leswing, K., Abel, R., Shoichet, B. K., & Jerome, S. V. (2021) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.1c00810 · Cited by 442
Gentile, F., Yaacoub, J. C., Gleave, J., Fernandez, M., Ton, A.-T., Ban, F., Stern, A., & Cherkasov, A. (2022) · Nature Protocols · doi:10.1038/s41596-021-00659-2 · Cited by 397
Self-citationIntegrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR
Tropsha, A., Isayev, O., Varnek, A., Schneider, G., & Cherkasov, A. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00832-0 · Cited by 397
Self-citationMachine-learning methods for ligand–protein molecular docking
Crampon, K., Giorkallos, A., Deldossi, M., Baud, S., & Steffenel, L. A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.007 · Cited by 388
Exposing the Limitations of Molecular Machine Learning with Activity Cliffs
van Tilborg, D., Alenicheva, A., & Grisoni, F. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01073 · Cited by 337
Accelerating high-throughput virtual screening through molecular pool-based active learning
Graff, D. E., Shakhnovich, E. I., & Coley, C. W. (2021) · Chemical Science · doi:10.1039/d0sc06805e · Cited by 302
Benchmarking AlphaFold‐enabled molecular docking predictions for antibiotic discovery
Wong, F., Krishnan, A., Zheng, E. J., Stärk, H., Manson, A. L., Earl, A. M., Jaakkola, T., & Collins, J. J. (2022) · Molecular Systems Biology · doi:10.15252/msb.202211081 · Cited by 284
“Model predictions based on the following rescoring functions were ensembled in sequence: RF-Score, NNScore, PLEC score, and RF-Score-VS.”
BackgroundMethodAn artificial intelligence accelerated virtual screening platform for drug discovery
(2024) · doi:10.1038/s41467-024-52061-7 · Cited by 259
The transformational role of GPU computing and deep learning in drug discovery
Pandey, M., Fernandez, M., Gentile, F., Isayev, O., Tropsha, A., Stern, A. C., & Cherkasov, A. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00463-x · Cited by 255
Self-citationA critical overview of computational approaches employed for COVID-19 drug discovery
Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01065k · Cited by 206
Self-citationBajorath, J., Chávez-Hernández, A. L., Duran-Frigola, M., Fernández-de Gortari, E., Gasteiger, J., López-López, E., Maggiora, G. M., Medina-Franco, J. L., Méndez-Lucio, O., Mestres, J., et al. (2022) · Journal of Cheminformatics · doi:10.1186/s13321-022-00661-0 · Cited by 38
Language models for the prediction of SARS-CoV-2 inhibitors
Blanchard, A. E., Gounley, J., Bhowmik, D., Chandra Shekar, M., Lyngaas, I., Gao, S., Yin, J., Tsaris, A., Wang, F., & Glaser, J. (2022) · The International Journal of High Performance Computing Applications · doi:10.1177/10943420221121804 · Cited by 30
Systemic evolutionary chemical space exploration for drug discovery
Lu, C., Liu, S., Shi, W., Yu, J., Zhou, Z., Zhang, X., Lu, X., Cai, F., Xia, N., & Wang, Y. (2022) · Journal of Cheminformatics · doi:10.1186/s13321-022-00598-4 · Cited by 30
NeuralDock: Rapid and Conformation-Agnostic Docking of Small Molecules
Sha, C. M., Wang, J., & Dokholyan, N. V. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.867241 · Cited by 9
“Deep neural networks for predicting binding af fi nities have been successful; however, there are drawbacks to speci fi c approaches (Cang et al., 2018; Jiménez et al., 2018; Francoeur et al., 2020; Gentile et al., 2020).”
Method
Metadata
- Authors
- Gentile, F., Agrawal, V., Hsing, M., Ton, A.-T., Ban, F., Norinder, U., Gleave, M. E., & Cherkasov, A.
- Venue
- ACS Central Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-05-19
- Volume
- 6
- Issue
- 6
- Pages
- 939-949
- ISSN
- 2374-7943 (ISSN-L)
- 2374-7951
- OpenAlex
- W3027975282
- Cited by
- 447
- References
- 40
- FWCI
- 24.89
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.